{
  "trial_id": "NCT02639182",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, sex, race, ECOG performance status, histological subtype (clear cell vs. non-clear cell), number of prior systemic regimens, prior anti-VEGF therapy, presence of measurable disease, absolute neutrophil count (ANC), platelet count, hemoglobin level, creatinine level, glomerular filtration rate (GFR), aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, total bilirubin level, prothrombin time (PT), activated partial thromboplastin time (aPTT), urine protein to creatinine ratio (uPCR), pregnancy status, breastfeeding status, use of contraception, history of brain metastasis, blood pressure, gastrointestinal abnormalities, ocular conditions, use of investigational drugs, sensitivity to study drugs, use of CYP3A4/5 inhibitors/inducers, history of thromboembolic events, history of bleeding disorders, history of cardiac disease, history of major surgery, presence of active infection, compliance with study requirements, presence of medical or psychiatric disorders.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status",
          "ECOG performance status"
        ],
        [
          "Histological Type",
          "histological subtype (clear cell vs. non-clear cell)"
        ],
        [
          "Number of Prior Systemic Renal cell carcinoma (RCC) Treatment Regimens",
          "number of prior systemic regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race/Ethnicity",
        "Prognostic Risk Group"
      ],
      "remaining_candidate_features": [
        "race",
        "prior anti-VEGF therapy",
        "presence of measurable disease",
        "absolute neutrophil count (ANC)",
        "platelet count",
        "hemoglobin level",
        "creatinine level",
        "glomerular filtration rate (GFR)",
        "aspartate aminotransferase (AST) level",
        "alanine aminotransferase (ALT) level",
        "total bilirubin level",
        "prothrombin time (PT)",
        "activated partial thromboplastin time (aPTT)",
        "urine protein to creatinine ratio (uPCR)",
        "pregnancy status",
        "breastfeeding status",
        "use of contraception",
        "history of brain metastasis",
        "blood pressure",
        "gastrointestinal abnormalities",
        "ocular conditions",
        "use of investigational drugs",
        "sensitivity to study drugs",
        "use of CYP3A4/5 inhibitors/inducers",
        "history of thromboembolic events",
        "history of bleeding disorders",
        "history of cardiac disease",
        "history of major surgery",
        "presence of active infection",
        "compliance with study requirements",
        "presence of medical or psychiatric disorders"
      ]
    },
    "processed-gen-response": "Age, sex, race, ECOG performance status, histological subtype (clear cell vs. non-clear cell), number of prior systemic regimens, prior anti-VEGF therapy, presence of measurable disease, absolute neutrophil count (ANC), platelet count, hemoglobin level, creatinine level, glomerular filtration rate (GFR), aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, total bilirubin level, prothrombin time (PT), activated partial thromboplastin time (aPTT), urine protein to creatinine ratio (uPCR), pregnancy status, breastfeeding status, use of contraception, history of brain metastasis, blood pressure, gastrointestinal abnormalities, ocular conditions, use of investigational drugs, sensitivity to study drugs, use of CYP3A4/5 inhibitors/inducers, history of thromboembolic events, history of bleeding disorders, history of cardiac disease, history of major surgery, presence of active infection, compliance with study requirements, presence of medical or psychiatric disorders."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Histological Subtype, Number of Prior Systemic Regimens, Prior Anti-VEGF Therapy, Measurable Disease per RECIST v1.1, Hematopoietic Function (ANC, Platelet Count, Hemoglobin), Renal Function (Creatinine, GFR), Hepatic Function (AST, ALT, Total Bilirubin), Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Urine Protein to Creatinine Ratio (uPCR),",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status",
          "ECOG Performance Status"
        ],
        [
          "Histological Type",
          "Histological Subtype"
        ],
        [
          "Number of Prior Systemic Renal cell carcinoma (RCC) Treatment Regimens",
          "Number of Prior Systemic Regimens"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Prognostic Risk Group"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Prior Anti-VEGF Therapy",
        "Measurable Disease per RECIST v1.1",
        "Hematopoietic Function (ANC, Platelet Count, Hemoglobin)",
        "Renal Function (Creatinine, GFR)",
        "Hepatic Function (AST, ALT, Total Bilirubin)",
        "Prothrombin Time (PT)",
        "Activated Partial Thromboplastin Time (aPTT)",
        "Urine Protein to Creatinine Ratio (uPCR)"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Histological Subtype, Number of Prior Systemic Regimens, Prior Anti-VEGF Therapy, Measurable Disease per RECIST v1.1, Hematopoietic Function (ANC, Platelet Count, Hemoglobin), Renal Function (Creatinine, GFR), Hepatic Function (AST, ALT, Total Bilirubin), Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), Urine Protein to Creatinine Ratio (uPCR)"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Histology (Clear Cell/Non-Clear Cell), Prior Systemic Regimens, Prior Anti-VEGF Regimens, Measurable Disease, Hematopoietic Function (ANC, Platelet Count, Hemoglobin), Renal Function (Creatinine, GFR), Hepatic Function (AST, ALT, Total Bilirubin), Prothrombin Time, Activated Partial Thromboplastin Time, Urine Protein to Creatinine Ratio.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race/Ethnicity",
          "Race/Ethnicity"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status",
          "ECOG Performance Status"
        ],
        [
          "Histological Type",
          "Histology (Clear Cell/Non-Clear Cell)"
        ],
        [
          "Number of Prior Systemic Renal cell carcinoma (RCC) Treatment Regimens",
          "Prior Systemic Regimens"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Prognostic Risk Group"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "Prior Anti-VEGF Regimens",
        "Measurable Disease",
        "Hematopoietic Function (ANC, Platelet Count, Hemoglobin)",
        "Renal Function (Creatinine, GFR)",
        "Hepatic Function (AST, ALT, Total Bilirubin)",
        "Prothrombin Time",
        "Activated Partial Thromboplastin Time",
        "Urine Protein to Creatinine Ratio."
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, ECOG Performance Status, Histology (Clear Cell/Non-Clear Cell), Prior Systemic Regimens, Prior Anti-VEGF Regimens, Measurable Disease, Hematopoietic Function (ANC, Platelet Count, Hemoglobin), Renal Function (Creatinine, GFR), Hepatic Function (AST, ALT, Total Bilirubin), Prothrombin Time, Activated Partial Thromboplastin Time, Urine Protein to Creatinine Ratio."
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, Sex, Race, ECOG performance status, Histological diagnosis of RCC (clear cell or non-clear cell), ENPP3 status, Prior systemic regimens, Prior anti-VEGF therapy, Measurable disease according to RECIST v.1.1, Hematopoietic function (ANC, Platelet count, Hemoglobin), Renal function (Creatinine, GFR), Hepatic function (AST, ALT, Total bilirubin), Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels, Urine Protein to Creatinine Ratio (uPCR).",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex"
        ],
        [
          "Eastern Cooperative Oncology Group (ECOG) Performance Status",
          "ECOG performance status"
        ],
        [
          "Histological Type",
          "Histological diagnosis of RCC (clear cell or non-clear cell)"
        ],
        [
          "Number of Prior Systemic Renal cell carcinoma (RCC) Treatment Regimens",
          "Prior systemic regimens"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race/Ethnicity",
        "Prognostic Risk Group"
      ],
      "remaining_candidate_features": [
        "Race",
        "ENPP3 status",
        "Prior anti-VEGF therapy",
        "Measurable disease according to RECIST v.1.1",
        "Hematopoietic function (ANC, Platelet count, Hemoglobin)",
        "Renal function (Creatinine, GFR)",
        "Hepatic function (AST, ALT, Total bilirubin)",
        "Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels",
        "Urine Protein to Creatinine Ratio (uPCR)"
      ]
    },
    "processed-gen-response": "Age, Sex, Race, ECOG performance status, Histological diagnosis of RCC (clear cell or non-clear cell), ENPP3 status, Prior systemic regimens, Prior anti-VEGF therapy, Measurable disease according to RECIST v.1.1, Hematopoietic function (ANC, Platelet count, Hemoglobin), Renal function (Creatinine, GFR), Hepatic function (AST, ALT, Total bilirubin), Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels, Urine Protein to Creatinine Ratio (uPCR)."
  }
}